CBM treatments may improve pain scores, but study limitations such as small sample sizes and study durations, high placebo response rates, and trial unblinding because of the psychoactive effects of cannabinoids all hinder data interpretation and the extrapolation to chronic pain conditions.
Ireland Moves Forward With Review of Medical Cannabis Programme
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchMedical Cannabis Clinical Summary Ireland is advancing its medical cannabis programme through a formal review...
Cannabis-based medicines for chronic neuropathic pain in adults.
Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neuropathic p…